| pubmed-article:15522471 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C0018801 | lld:lifeskim |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C0018787 | lld:lifeskim |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C0205245 | lld:lifeskim |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C0026565 | lld:lifeskim |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C0717550 | lld:lifeskim |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C0026538 | lld:lifeskim |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C0004083 | lld:lifeskim |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C0301630 | lld:lifeskim |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:15522471 | lifeskim:mentions | umls-concept:C0027976 | lld:lifeskim |
| pubmed-article:15522471 | pubmed:issue | 21 | lld:pubmed |
| pubmed-article:15522471 | pubmed:dateCreated | 2004-11-3 | lld:pubmed |
| pubmed-article:15522471 | pubmed:abstractText | To evaluate the effect of the angiotensin receptor blocker candesartan on New York Heart Association (NYHA) functional class in a broad spectrum of patients with chronic heart failure (CHF). | lld:pubmed |
| pubmed-article:15522471 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15522471 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15522471 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15522471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15522471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15522471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15522471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15522471 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15522471 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:15522471 | pubmed:issn | 0195-668X | lld:pubmed |
| pubmed-article:15522471 | pubmed:author | pubmed-author:McMurrayJohnJ | lld:pubmed |
| pubmed-article:15522471 | pubmed:author | pubmed-author:YusufSalimS | lld:pubmed |
| pubmed-article:15522471 | pubmed:author | pubmed-author:SwedbergKarlK | lld:pubmed |
| pubmed-article:15522471 | pubmed:author | pubmed-author:YoungJames... | lld:pubmed |
| pubmed-article:15522471 | pubmed:author | pubmed-author:PfefferMarcM | lld:pubmed |
| pubmed-article:15522471 | pubmed:author | pubmed-author:OlofssonBerti... | lld:pubmed |
| pubmed-article:15522471 | pubmed:author | pubmed-author:SolomonScottS | lld:pubmed |
| pubmed-article:15522471 | pubmed:author | pubmed-author:MichelsonEric... | lld:pubmed |
| pubmed-article:15522471 | pubmed:author | pubmed-author:O'MearaEileen... | lld:pubmed |
| pubmed-article:15522471 | pubmed:author | pubmed-author:GrangerChrisC | lld:pubmed |
| pubmed-article:15522471 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15522471 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:15522471 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15522471 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15522471 | pubmed:pagination | 1920-6 | lld:pubmed |
| pubmed-article:15522471 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15522471 | pubmed:meshHeading | pubmed-meshheading:15522471... | lld:pubmed |
| pubmed-article:15522471 | pubmed:meshHeading | pubmed-meshheading:15522471... | lld:pubmed |
| pubmed-article:15522471 | pubmed:meshHeading | pubmed-meshheading:15522471... | lld:pubmed |
| pubmed-article:15522471 | pubmed:meshHeading | pubmed-meshheading:15522471... | lld:pubmed |
| pubmed-article:15522471 | pubmed:meshHeading | pubmed-meshheading:15522471... | lld:pubmed |
| pubmed-article:15522471 | pubmed:meshHeading | pubmed-meshheading:15522471... | lld:pubmed |
| pubmed-article:15522471 | pubmed:meshHeading | pubmed-meshheading:15522471... | lld:pubmed |
| pubmed-article:15522471 | pubmed:meshHeading | pubmed-meshheading:15522471... | lld:pubmed |
| pubmed-article:15522471 | pubmed:meshHeading | pubmed-meshheading:15522471... | lld:pubmed |
| pubmed-article:15522471 | pubmed:meshHeading | pubmed-meshheading:15522471... | lld:pubmed |
| pubmed-article:15522471 | pubmed:meshHeading | pubmed-meshheading:15522471... | lld:pubmed |
| pubmed-article:15522471 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15522471 | pubmed:articleTitle | Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. | lld:pubmed |
| pubmed-article:15522471 | pubmed:affiliation | Department of Cardiology, Western Infirmary, Glasgow, Scotland, UK. | lld:pubmed |
| pubmed-article:15522471 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15522471 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15522471 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:15522471 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15522471 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15522471 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15522471 | lld:pubmed |
